Leptin in the treatment of lipodystrophy due to type 1 diabetes mellitus: integrative review
Leptina no tratamento da lipodistrofia em decorrência da diabetes mellitus tipo 1: revisão integrativa
DOI:
https://doi.org/10.53660/CLM-3332-24H41Palavras-chave:
Diabetes mellitus, Diabetes, Insulin, Lipodystrophy, LeptinResumo
Objective: To analyze the benefits of treatment with Recombinant Human Leptin in areas presenting Lipodystrophy and its impacts on serum levels of Glycemia and Glycated Hemoglobin. Methods: This is an integrative review, in which data collection was conducted in the PubMed database. Twelve articles were selected from the period 2002 to 2020. Results: Treatment of Lipodystrophy through Recombinant Human Leptin has been studied over the years to prevent and delay the onset of this alteration. Leptin replacement is performed in individuals with Lipodystrophy. Administration of this hormone attenuated hypoleptinemia, and consequently moderated adipose tissue degradation and glycemic control, resulting in improved insulin resistance. Conclusion: It is concluded that treatment with leptin directly influences the improvement of clinical and laboratory signs of Lipodystrophy, preventing rapid progression of adipose tissue degradation and glycemic imbalance, as well as reducing levels of Glycated Hemoglobin.
Downloads
Referências
ARAUJO-VILAR, D. et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine, v. 49, n. 1, 2015.
BROWN, R. J. et al. Effects of metreleptin in pediatric patients with lipodystrophy. Journal of Clinical Endocrinology and Metabolism, v. 102, n. 5, 2017.
BROWN, R. J. et al. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. Journal of Clinical Investigation, v. 128, n. 8, 2018.
CAPEAU, J. et al. Human lipodystrophies: Genetic and acquired diseases of adipose tissue. Endocrine Development, 2010.
CHAN, J. et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocrine Practice, v. 17, n. 6, 2011.
CHONG, A. Y. et al. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia, v. 53, n. 1, 2010.
DIKER-COHEN, T. et al. Partial and generalized lipodystrophy: Comparison of baseline characteristics and response to metreleptin. Journal of Clinical Endocrinology and Metabolism, v. 100, n. 5, 2015.
EBIHARA, K. et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. Journal of Clinical Endocrinology and Metabolism, v. 92, n. 2, 2007.
FABIANO TONDELLO; LIANE EINLOF; MÁRJORI DA SILVA. AVALIAÇÃO DE ENFERMAGEM EM CRIANÇAS DIABETES MELLITUS TIPO 1 COM LIPODISTROFIA INSULÍNICA. Rev. Soc. Bras. Enferm. Ped, v. 7, n. 1, p. 7–15, 2007.
FAMULLA, S. et al. Insulin injection into lipohypertrophic tissue: Blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care, v. 39, n. 9, 2016.
GREWAL, S. et al. Metabolomic analysis of the effects of leptin replacement therapy in patients with lipodystrophy. Journal of the Endocrine Society, v. 4, n. 1, 2020.
JAVOR, E. D. et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes, v. 54, n. 7, 2005.
KAMRAN, F. et al. Consequences of stopping and restarting Leptin in an adolescent with lipodystrophy. Hormone Research in Paediatrics, v. 78, n. 5–6, 2012.
LUCCHETTI, G. et al. Hipertrigliceridemia grave na cetoacidose diabética: relato de caso. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 53, n. 7, 2009.
MAINIERI, F.; CHIARELLI, F. Lipodystrophies in Children. Hormone Research in Paediatrics, 2022.
MUNIYAPPA, R. et al. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy. Diabetes Care, v. 37, n. 4, 2014.
NEGRÃO, A. B.; LICINIO, J. Leptina: o diálogo entre adipócitos e neurônios. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 44, n. 3, 2000.
ORAL, E. A. et al. Leptin-Replacement Therapy for Lipodystrophy. New England Journal of Medicine, v. 346, n. 8, 2002.
ÖZEN, S.; AKINCI, B.; ORAL, E. A. Current diagnosis, treatment and clinical challenges in the management of lipodystrophy syndromes in children and young people. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2020.
PARK, J. Y. et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: The effect of long-term leptin therapy. Journal of Clinical Endocrinology and Metabolism, v. 93, n. 1, 2008.
RIBEIRO FILHO, F. F. et al. Gordura visceral e síndrome metabólica: Mais que uma simples associação. Arquivos Brasileiros de Endocrinologia e Metabologia, 2006.
RODRIGUEZ, A. J.; MASTRONARDI, C. A.; PAZ-FILHO, G. J. New advances in the treatment of generalized lipodystrophy: Role of metreleptin. Therapeutics and Clinical Risk Management, 2015.
